BR112022008753A2 - Tratamentos de câncer direcionados a células-tronco cancerosas - Google Patents

Tratamentos de câncer direcionados a células-tronco cancerosas

Info

Publication number
BR112022008753A2
BR112022008753A2 BR112022008753A BR112022008753A BR112022008753A2 BR 112022008753 A2 BR112022008753 A2 BR 112022008753A2 BR 112022008753 A BR112022008753 A BR 112022008753A BR 112022008753 A BR112022008753 A BR 112022008753A BR 112022008753 A2 BR112022008753 A2 BR 112022008753A2
Authority
BR
Brazil
Prior art keywords
cancer
compounds
stem cells
kits
compositions
Prior art date
Application number
BR112022008753A
Other languages
English (en)
Inventor
Bhurruth-Alcor Yushma
Thomas Crimmins Gregory
Alexandra De Jesús Diaz Dennise
Mae Robb Caroline
Original Assignee
Remedy Plan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Plan Inc filed Critical Remedy Plan Inc
Publication of BR112022008753A2 publication Critical patent/BR112022008753A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

TRATAMENTOS DE CÂNCER DIRECIONADOS A CÉLULAS-TRONCO CANCERÍGENAS. A presente invenção refere-se a compostos, métodos, composições, usos e kits que permitem o tratamento de câncer. Em algumas modalidades, os compostos são usados para tratar doenças ou distúrbios. Os compostos podem tratar o câncer tendo as células-tronco como alvos. Em algumas modalidades, o câncer é câncer colorretal, câncer gástrico, tumor estromal gastrointestinal, câncer ovariano, câncer do pulmão, câncer da mama, câncer pancreático, câncer da próstata, câncer testicular, linfoma, câncer do fígado, câncer endometrial, leucemia, ou mieloma múltiplo. A invenção fornece compostos, métodos, composições, usos e kits que podem ser usados em medicina regenerativa. Os compostos usados na presente invenção apresentam as Fórmulas (0) e (l).
BR112022008753A 2019-11-06 2020-11-06 Tratamentos de câncer direcionados a células-tronco cancerosas BR112022008753A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931531P 2019-11-06 2019-11-06
PCT/US2020/059329 WO2021092322A1 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Publications (1)

Publication Number Publication Date
BR112022008753A2 true BR112022008753A2 (pt) 2022-07-19

Family

ID=73643356

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008753A BR112022008753A2 (pt) 2019-11-06 2020-11-06 Tratamentos de câncer direcionados a células-tronco cancerosas

Country Status (12)

Country Link
US (1) US20230023124A1 (pt)
EP (1) EP4055008A1 (pt)
JP (1) JP2022553865A (pt)
KR (1) KR20220110744A (pt)
CN (1) CN114929672A (pt)
AU (1) AU2020378067A1 (pt)
BR (1) BR112022008753A2 (pt)
CA (1) CA3157315A1 (pt)
CO (1) CO2022007910A2 (pt)
IL (1) IL292718A (pt)
MX (1) MX2022005445A (pt)
WO (1) WO2021092322A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
WO2008016643A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
EP2866791A4 (en) 2012-05-07 2016-04-20 Gen Hospital Corp NOVEL COMPOSITIONS AND USES BLOOD PRESSURE RECIPROCATORS FOR CANCER THERAPY
US9381253B2 (en) 2013-04-09 2016-07-05 Massachusetts Institute Of Technology Drug delivery polymer and uses thereof
CN112312899A (zh) * 2018-05-04 2021-02-02 治疗方案股份有限公司 靶向癌症干细胞的癌症治疗

Also Published As

Publication number Publication date
IL292718A (en) 2022-07-01
MX2022005445A (es) 2022-08-10
AU2020378067A1 (en) 2022-05-26
CN114929672A (zh) 2022-08-19
KR20220110744A (ko) 2022-08-09
US20230023124A1 (en) 2023-01-26
WO2021092322A1 (en) 2021-05-14
CA3157315A1 (en) 2021-05-14
JP2022553865A (ja) 2022-12-26
EP4055008A1 (en) 2022-09-14
CO2022007910A2 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
AU2016256469A8 (en) Methods for treating cancer
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
BR112019010020A2 (pt) compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
EA201991622A1 (ru) Комплексная терапия для лечения рака
BR112017006464A2 (pt) bloqueio de cd73
BR112018070161A2 (pt) moduladores de receptores de estrogênio
DOP2022000194A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
MA40074A (fr) Composés liant ras multivalents
BR112021025102A2 (pt) Derivados de quinazolin-4-ona úteis para o tratamento de doenças e distúrbios associados a braf
BR112022024597A2 (pt) Compostos de 4-oxo-3,4-di-hidroquinazolinona para o tratamento de doenças e distúrbios associados com braf
NZ584042A (en) Use of mva to treat prostate cancer
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
CO6280405A2 (es) Composiciones y metodos de uso de la quinasa -1 similar al receptor de la activina
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
BR112021026498A2 (pt) Composto, uso do composto e composição farmacêutica
MA40075A (fr) Combinaisons pour traiter des cancers
BR112014016635B8 (pt) composto, composição, e, uso de um composto
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
BR112022008753A2 (pt) Tratamentos de câncer direcionados a células-tronco cancerosas
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma